Abstract

In this case, we report tumor lysis syndrome (TLS) in a patient with metastatic nasopharyngeal carcinoma treated with pembrolizumab. There are only a few studies reporting the development of TLS associated with pembrolizumab, but this is the first report to include a patient with nasopharyngeal carcinoma. We think that this case report may help us to improve our current understanding of TLS in solid tumors, particularly nasopharyngeal carcinoma. We also believe that there should be a multidisciplinary treatment and prophylactic approach for TLS, a potentially fatal complication associated with pembrolizumab treatment.

Cite this article as:

Turhan A, Hannarici Z, Büyükbayram ME, et al. Tumor lysis syndrome due to pembrolizumab use in metastatic nasopharyngeal carcinoma. Arch Basic Clin Res. 2024;6(1):73-76.